2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1033

Comparison of Oral Administration of Diacerein, Intra-Articular Injection of Diacerein Solution, and Intra-Articular Injection of Diacerein-Loaded Nanoparticle in Osteoarthritis Rat Model
Abstract Number: 414

Comparison of Physical Activity Measures Derived from the Fitbit Flex and the Actigraph GT3x+ in an Employee Population with Chronic Knee Symptoms
Abstract Number: 2487

Comparison of QOL Evaluation Using EQ-5D-3L and EQ-5D-5L in Japanese RA Patients: A Study Using the IORRA Cohort
Abstract Number: 403

Comparison of Radial Extracorporeal Shock Wave Therapy and Traditional Physiotherapy in Rotator Cuff Calcific Tendinitis Treatment
Abstract Number: 287

Comparison of Real-World Costs between Patients with Rheumatoid Arthritis Treated with Subcutaneously-Administered Biologics Previously Treated with Another Biologic
Abstract Number: 2485

Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Abstract Number: 1322

Comparison of Serum Hepcidin and Calprotectin Levels in Patients with Familial Mediterranean Fever (FMF) and Healthy Subjects
Abstract Number: 2907

Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Abstract Number: 2408

Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis
Abstract Number: 1214

Comparison of Ultrasound Features of Major Salivary Glands in Sarcoidosis, Amyloidosis, and Sjögren’s Syndrome
Abstract Number: 2718

Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort
Abstract Number: 2833

Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Abstract Number: 2630

Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 2940

Complementary Practices As Alternatives to Pain: Effectiveness of a Pain Management Program for Patients in an Orthopedic Clinic
Abstract Number: 2300

Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].